The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
The proposed EHDS Regulation1 (Proposal), introduced in May 2022 by the European Commission (EC), aims to reform the “situation of fragmentation” that depicts th